Cerebrolysin
Also known as: FPE 1070
Popular For
Brain injury recovery, cognitive decline, neurodegeneration
Key Facts: Cerebrolysin
- Category
- Cognitive
- FDA Status
- Not FDA Approved
- Clinical Status
- Approved in 40+ countries - Not FDA approved
- Administration
- Intravenous or intramuscular injection
- Typical Dose
- 5-10 ml IV/IM daily for 10-20 days
- Frequency
- Daily during treatment cycles
- Evidence Level
- Human Trials
- Duration
- 10-20 day cycles
Mechanism of Action
Cerebrolysin contains neurotrophic factors that mimic BDNF, NGF, and CNTF activity. It enhances neuroplasticity, protects neurons from excitotoxicity, promotes neurogenesis, and improves synaptic function.
Research Summary
Approved in over 40 countries for neurological conditions. Studies show benefits in stroke recovery, Alzheimer's disease, and TBI. Large clinical trials demonstrate improved cognitive function and activities of daily living.
Dosing Information
Typical Dosingⓘ
Community experience
5-10 ml IV/IM daily for 10-20 days
5-30 ml per day
Daily during treatment cycles
Neuropeptide mixture requiring injection. Used in cycles. Approved in some countries for cognitive disorders.
Research Dosingⓘ
Scientific studies
Doses from clinical practice
Doses from Studies
10-30 mL daily IV for acute conditions
5-10 mL IM for maintenance
Duration
10-20 day cycles
Administration
Intravenous or intramuscular injection
Timing & Administration
Best Time to Take
Morning
Once daily, often in cycles
Food Recommendation
With or without food
Why This Timing?
Cerebrolysin supports cognitive function. Morning use aligns with peak cognitive demands.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Dizziness
- ●Headache
- ●Nausea
- ●Agitation
- ●Confusion
- ●Anaphylactic shock (rare)
- ●Not FDA approved in US
References
Related Peptides
Peptides commonly compared with Cerebrolysin or used in similar applications.
Selank
Clinical TrialsA synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.
CognitiveSemax
Clinical TrialsA synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Approved in Russia for stroke and cognitive enhancement. Known for nootropic and neuroprotective effects.
CognitiveDihexa
PreclinicalA potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.
CognitiveGB-115
Clinical TrialsA dipeptide anxiolytic and nootropic that acts as a CCK-1 (cholecystokinin) receptor antagonist. Developed in Russia with completed Phase 3 trials for anxiety. Users report significant improvements in focus, attention, and ADHD-like symptoms.
CognitiveNormoftal
Clinical TrialsA synthesized Khavinson peptide bioregulator containing short peptides (2-4 amino acids) derived from retinal tissue. Developed to normalize retinal function and support eye health. Clinical studies in Russia report improved visual function in 95% of patients with various retinal pathologies.
CognitivePE-22-28
PreclinicalA synthetic heptapeptide (7 amino acids) derived from Spadin, a naturally occurring antidepressant peptide. PE-22-28 is a shorter, more stable analog that retains the antidepressant and anxiolytic properties of Spadin. Works by blocking TREK-1 potassium channels in the brain.
CognitiveLooking for a trusted vendor?
Pro members get access to verified vendors with quality standards & exclusive discount codes.
Want updates on Cerebrolysin research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.